Benjamin Weinberg, MD
Hematology & Oncology · Washington, DCNPI 1598064941
Payments from drug & device makers
Across 531 payments — averaging $13,699 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ipsen Biopharmaceuticals, Inc$4.2M
- Merck$1.7M
- E.r. Squibb & Sons, L.L.C.$308K
- Pfizer$284K
- Janssen Research & Development, LLC$146K
- G1 Therapeutics, Inc.$101K
- plus $580K from 29 others
What the payments were for
- Consulting fees$44,00914%
- Speaking & faculty fees$250,27777%
- Travel & lodging$24,6058%
- Food & beverage$6,5842%
- Education$1000%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ipsen Biopharmaceuticals, Inc | 61 | $4,156,580 |
| Merck | 9 | $1,699,397 |
| E.r. Squibb & Sons, L.L.C. | 9 | $308,056 |
| Pfizer | 40 | $283,565 |
| Janssen Research & Development, LLC | 10 | $145,824 |
| G1 Therapeutics, Inc. | 22 | $101,191 |
| Exelixis Inc. | 19 | $78,782 |
| Seagen Inc. | 44 | $72,815 |
| Sirtex Medical Inc | 57 | $63,767 |
| Jazz Pharmaceuticals Inc. | 42 | $57,099 |
| Bayer | 65 | $50,459 |
| AstraZeneca | 4 | $41,456 |
| Array Biopharma Inc | 16 | $36,752 |
| Taiho Oncology, Inc. | 27 | $36,601 |
| Incyte Corporation | 6 | $33,525 |
| Genentech, Inc. | 1 | $32,940 |
| Lilly USA, LLC | 35 | $17,109 |
| Macrogenics, Inc. | 3 | $7,656 |
| Regeneron | 9 | $7,443 |
| Astrazeneca UK Limited | 1 | $7,250 |
| Foundation Medicine, Inc. | 4 | $7,096 |
| Partner Therapeutics, Inc. | 14 | $7,047 |
| Novartis | 1 | $5,076 |
| Boehringer Ingelheim International GmbH | 13 | $4,384 |
| Daiichi Sankyo Inc. | 3 | $4,325 |
| Halozyme Inc | 2 | $3,818 |
| Boehringer Ingelheim | 1 | $1,740 |
| Blueprint Medicines Corporation | 1 | $1,386 |
| Caris MPI, Inc. | 2 | $450 |
| Intera Oncology, Inc | 2 | $281 |
| Immunocore Limited | 1 | $142 |
| Beigene USA, Inc. | 4 | $66 |
| Tersera Therapeutics LLC | 1 | $35 |
| Angiodynamics, Inc. | 1 | $32 |
| Regeneron Healthcare Solutions, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,274,164 in reported general payments places this provider in the 95th percentile of 69 hematology & oncology providers in District of Columbia.
See all hematology & oncology providers in District of Columbia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Sunitinib Malate | 13 | $168,997 |
| LonsurfTrifluridine/Tipiracil Hcl | 12 | $81,610 |
| Abiraterone Acetate | 12 | $67,019 |
| CreonLipase/Protease/Amylase | 29 | $48,010 |
| EliquisApixaban | 37 | $33,160 |
| Morphine Sulfate ErMorphine Sulfate | 22 | $893 |
| Oxycodone Hcl | 34 | $758 |
| Prednisone | 19 | $222 |
| Prochlorperazine Maleate | 22 | $182 |
| Ondansetron Hcl | 23 | $136 |
| Pantoprazole Sodium | 22 | $88 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Taiho Oncology, Inc.Lonsurf | $36,601 | $81,61012 claims |
| PfizerEliquis | $283,565 | $33,16037 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 69 hematology & oncology providers in District of Columbia.
Other hematology & oncology in Washington
- Pavani ChalasaniWashington$10.3M
- Chul KimWashington$8.4M
- Vered StearnsWashington$7.8M
- Claudine IsaacsWashington$5.3M
- Julie BaumanWashington$3.4M
- Catherine BroomeWashington$2.9M
- Suthee RapisuwonWashington$1.9M
- Julie CollinsWashington$1.8M
- Ami ChitaliaWashington$1.8M
- Imadeddine TabbaraWashington$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.